COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT01128712
Previous Study | Return to List | Next Study

Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01128712
Recruitment Status : Terminated (lack of enrollment. terminated in 2014. no data analysis.)
First Posted : May 24, 2010
Last Update Posted : September 14, 2017
Information provided by (Responsible Party):
Evan Fertig, Northeast Regional Epilepsy Group

Tracking Information
First Submitted Date  ICMJE May 20, 2010
First Posted Date  ICMJE May 24, 2010
Last Update Posted Date September 14, 2017
Study Start Date  ICMJE April 2010
Actual Primary Completion Date July 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 21, 2010)
Change in Beck Anxiety Score [ Time Frame: week 0 - week 6 ]
The primary outcome variable will be the change in the Beck Anxiety Inventory (BAI) score as measured at the baseline and final visits.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 21, 2010)
Change in BDI , NHS3 , STAI , NDDI-E and seizure frequency [ Time Frame: week 0 - week 6 ]
The secondary outcome variables will be the change in the Beck Depression Inventory, change in National Hospital Seizure Severity Scale (NHS3) score, change in seizure frequency, change in Stait-Trait Anxiety Scale (STAI),and change in the National Disorders Depression Inventory for Epilepsy Screening Tool (NDDI-E) as measured at the baseline and final visits.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin
Official Title  ICMJE An Open Label, Randomized Study Prospectively Examining the Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin
Brief Summary To prospectively demonstrate the superior anxiolytic effect of high dose pregabalin (PGB) therapy (450 mg/day) compared to low dose PGB therapy (150 mg/day) in subjects with medically refractory partial epilepsy not fully controlled despite treatment with 1-2 concomitant antiepileptic drugs (AEDs).
Detailed Description


Interictal anxiety symptoms are reported in two-thirds of patients with epilepsy and represent an underrecognized and undertreated aspect of the disorder. Interictal anxiety is postulated to stem from both fear of seizure recurrence ("seizure phobia") and dispersed locus of control.In addition, anxiety and the most common forms of partial onset epilepsy are viewed to arise from dysfunction in a common neurobiological substrate-the amygdala and other structures within the limbic system.

Background on Pregabalin

Pregabalin (CI-1008,Lyrica) is a chemical analogue of the mammalian neurotransmitter gamma-aminobutyric acid (GABA),although it does not bind to or activates GABA receptors or inhibit GABA uptake. Pregabalin is an alpha-2-delta ligand that has analgesic, anxiolytic, and antiepileptic activity.


Antiepileptic drugs (AEDs) are commonly used for mood disorders including anxiety.Pregabalin (PGB) the most recently FDA-approved AED for add-on therapy for refractory partial seizures also has demonstrated efficacy in Generalized Anxiety Disorder. PGB binds to the alpha-2-delta subunit protein of voltage-gated calcium channels, and in animal models, has anxiolytic and anti-epileptic effects via pre-synaptic inhibition of the release of several excitatory neurotransmitters.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Epilepsy, Complex Partial
Intervention  ICMJE
  • Drug: Pregabalin
    150 mg /day
    Other Name: Lyrica
  • Drug: Pregabalin
    450 mg/day
    Other Name: Lyrica
Study Arms  ICMJE
  • Group 1
    Pregabalin (150mg/day)
    Intervention: Drug: Pregabalin
  • Group 2
    Pregabalin (450mg/day)
    Intervention: Drug: Pregabalin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: September 23, 2014)
Original Estimated Enrollment  ICMJE
 (submitted: May 21, 2010)
Actual Study Completion Date  ICMJE July 2014
Actual Primary Completion Date July 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  • An IRB-approved consent form signed and dated by the subject
  • A diagnosis of partial epilepsy which is drug resistant according to the International League Against Epilepsy criteria (Failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom). Furthermore to meet the ILAE definition of drug resistance, subjects will have had breakthrough seizures occurring at a frequency of less than 3 times the longest pretreatment interseizure interval or every 12 months, which ever is longer.
  • Subjects that score ≥18 on Beck Anxiety Inventory will be included in the study
  • Subjects from 18 to 75 years, both inclusive.
  • Females without childbearing potential or childbearing potential using medically accepted forms of birth control (pre-menarcheal, post-menopausal, bilateral oophorectomy or tubal ligation, complete hysterectomy, or medically accepted form of contraception).
  • Subject judged by the Investigator to be reliable and capable of adhering to the protocol, visit schedules, and able to understand and complete study instruments.
  • CT or MRI scan performed within 2 years of screening and without evidence of a progressive lesion or neurological condition.
  • Electroencephalogram consistent with partial epilepsy and does not demonstrate generalized spike wave.
  • Currently treated with a stable dose of 1-2 AEDs for a minimum of 4 weeks (3 months for phenobarbital and primidone). Benzodiazepines used as a rescue therapy for seizures and used no more than once a week will be permitted.

Exclusion Criteria

  • History of psychogenic non-epileptic seizures.
  • The subject is pregnant or lactating.
  • Women with reproductive potential who refuse to use medically accepted forms of birth control.
  • Presence of any clinically significant laboratory abnormality which in the judgement of the investigator should exclude the subject from the study.
  • Presence of any progressive, demyelinating, or degenerative neurological condition.
  • Subject is currently taking gabapentin.
  • History of an allergic reaction to gabapentin or PGB.
  • History of worsened seizures or serious adverse reactions to gabapentin.
  • History of suicide attempt.
  • No active suicidal plan/intent or active suicidal thoughts in the last 6 months.
  • Current use or use within the previous three months prior to screening of antidepressant, anxiolytic, or antipsychotic agents. Subjects using benzodiazepines for anxiety will not be permitted.
  • Diagnosis of Bipolar Disorder, Schizophrenia, psychotic disorder (excluding post-ictal psychosis), Major Depression requiring hospitalization in the past 2 years, or other psychological or behavioral condition which in the judgement of the investigator should exclude the subject from the study.
  • A history of alcoholism, drug abuse, or drug addiction within the last 2 years.
  • Any contraindication to use of PGB.
  • Any clinical condition (e.g. severe renal impairment, chronic hepatic disease, serious infection, and or bone marrow depression) which will impair participation in the trial.
  • History of multiple drug allergies or severe drug allergy.
  • Subjects with vagal nerve stimulators (VNS).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01128712
Other Study ID Numbers  ICMJE NEREG-001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Evan Fertig, Northeast Regional Epilepsy Group
Study Sponsor  ICMJE Northeast Regional Epilepsy Group
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator: Evan Fertig, MD Northeast Regional Epilepsy Group
PRS Account Northeast Regional Epilepsy Group
Verification Date September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP